Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Aligos Therapeutics Inc. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners, which means that the company is currently interfacing with multiple individuals at the patent office. This distribution can lead to varied prosecution experiences depending on each examiner's approach to the 2 pending office actions.
The portfolio involves 2 distinct art units, indicating that the active cases fall into different technical sub-specialties. CHONG, KIMBERLY is the busiest examiner, currently holding 1 pending action. Given that there are 2 distinct examiners, each is responsible for a portion of the workload. This split across 2 distinct art units suggests a decentralized prosecution landscape for the company's current biotechnology applications. Practitioners should be mindful of the procedural nuances that may exist between the different art units involved. The 1 pending action under CHONG, KIMBERLY represents a specific portion of the current office action activity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, KIMBERLY | 1 | 72.3% | +13.1% |
| ANGELL, JON E | 1 | 71.1% | +21.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18122433 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | CHONG, KIMBERLY | — |
| 17194079 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ANGELL, JON E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18122433 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | CHONG, KIMBERLY | — |
| 17194079 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ANGELL, JON E | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18122433 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | CHONG, KIMBERLY | 1636 | §102§103§112 | Non-Final OA | — | Pending | Mar 16, 2023 |
| 17194079 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ANGELL, JON E | 1637 | §102§103§112Other | Non-Final OA | — | Pending | Mar 05, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAligos Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kimberly Chong has the most, with 1 of Aligos Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
